Journal
VACCINE
Volume 25, Issue -, Pages B61-B71Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.06.038
Keywords
cancer; immunotherapy; antigens; MAGE-A3
Categories
Ask authors/readers for more resources
From the first evidence that the immune system could recognize tumors, different types of tumor antigens have been identified and deeply characterized. Several different approaches aimed at targeting these antigens have already been the subject of clinical studies. In this field, the GSK Biologicals' approach relying on recombinant proteins combined with an immunological Adjuvant System in a specific clinical setting, has entertained hopes of developing a new class of well tolerated anti-cancer therapy. This methodology led to promising advances with MAGE-A3 immunotherapy in NSCLC and has the potential to be applied to all tumor types. (C) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available